Regenxbio
RGNX
181 hedge funds and large institutions have $512M invested in Regenxbio in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 48 reducing their positions, and 30 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 48
1.89% more ownership
Funds ownership: 86.93% → 88.82% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 188 → 181 (-7)
17% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 30
18% less call options, than puts
Call options by funds: $850K | Put options by funds: $1.04M
43% less capital invested
Capital invested by funds: $896M → $512M (-$385M)
Top Buyers
| 1 |
BlackRock
New York
|
+$15.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$9.16M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.69M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$2.96M |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$11.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.88M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.48M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$2.63M |
| 5 |
Morgan Stanley
New York
|
-$2.49M |
RGNX Hedge Fund Activity: Q2 2024 in Review
181 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2024, worth a combined $512M — down 43% from $896M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of RGNX and 25 opened new positions — a net loss of 5 holders — while 48 trimmed existing stakes and 74 added.
The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was JP Morgan Chase, cutting an estimated $11.1M.
- 181 institutional investors held Regenxbio (RGNX) as of Q2 2024, down from 188 in Q1 2024.
- Funds reported $512M of Regenxbio stock for Q2 2024, down 43% quarter-over-quarter.
- 25 funds opened new Regenxbio positions in Q2 2024 and 30 closed out, a net change of -5 holders.
- The largest Regenxbio buyer in Q2 2024 was BlackRock, an estimated $15.7M added.
- The largest Regenxbio seller in Q2 2024 was JP Morgan Chase, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2024.